LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

EPSCO Council conclusions: EuropaBio calls for more pragmatic approach addressing access, availability and affordability of medicines

16/06/2021
PRESS RELEASE

EPSCO Council conclusions: EuropaBio calls for more pragmatic approach addressing access, availability and affordability of medicines

Brussels, Belgium – 16 June 2021 – EuropaBio shares the EPSCO focus on improving the access, availability, and affordability of innovative medicines in the EU, through closer cooperation between Member States and their national medicine agencies, competent authorities, the European Commission and the European Medicines Agency.

‘Whilst we support the Council’s conclusions, we encourage a reality check applied to all key aspects of access, availability and affordability of medicines. Only through better stakeholder involvement in complex processes, and better cooperation between Member States, national agencies, the European Commission and the European Medicines Agency can significant improvements be delivered. Finally, ongoing activities around pharmaceutical legislation revision, in which EuropaBio is actively involved, could facilitate stakeholder inclusion and contribute to a both holistic and pragmatic approach.’, says Dr Claire Skentelbery, Director General of EuropaBio.

Availability

On availability of innovative medicines, we call on the European Commission and national health ministries to take decisive and long-needed steps to achieve better regulatory efficiency, through:

- making EU regulatory processes easy to navigate, swifter and up to date with science and technology to truly support innovation by ground-breaking biotechnology SMEs.

- expediting regulatory pathways in critical areas of unmet needs. For example, this could partially be achieved through simplifying and accelerating GMO assessment processes (e.g. via an exemption scheme for clinical trials with investigational advanced therapies), and through a flexible PRIME scheme with clear and accelerated access pathways for eligible products, combined with the capacity to provide rapid scientific advice.

- accepting fit-for-purpose RWE for regulatory benefit-risk assessment to drive clinical development, and decentralised and single-arm clinical trials to speed up access to novel technologies.

EuropaBio welcomes the Council’s acknowledgment that incentives for innovation “support the development of new effective and accessible medicines and medical devices.” This has proven especially true, as shown by the significant in the increase of new medicines developed for rare diseases. Following the introduction of incentives for the development of rare diseases in the year 2000, over 2200 treatments in development were granted “orphan” status 1.

Accessibility

On access, EuropaBio welcomes the Council’s encouragement to further stimulate R&D in areas of unmet medical need (UNM) However, the definition of unmet medical should remain broad, as UNM does not only exist in conditions with no currently approved treatment. Many conditions, for which treatments exist, continue to suffer from UNM and can be significantly improved (e.g. reducing disease severity, treatment burden, or increasing life expectancy etc.) Any additional incentives aimed at encouraging R&D in these conditions should complement, not replace, existing incentives in order to build upon prior successes. Finally, we believe it is of utmost importance that principles, criteria, or guidelines on UNM must be developed in a multi-stakeholder forum, where the patient’s voice is at the forefront. We would like to note that cell and gene therapies require highly specialised physicians and hospitals working in networks of reference centres. For rare diseases with limited patient numbers, it is impractical for each Member State to have a dedicated treatment centre, which needs to treat a certain number of patients per year to ensure that trained and certified medics deliver high-quality treatment. It is through better-functioning EU cross-border healthcare legislation that we can ensure patients have access to specialised treatments and novel therapies when these are not available in their home country.

Affordability

On affordability, we stress the emergence of highly targeted and effective biotechnology-derived advanced therapies opening new treatment horizons in the area of complex genetic and rare diseases which necessitate the employment of new pricing models. Through the structured dialogue of the Industrial Strategy we support the further enhancement of manufacturing agility and flexibility by adopting modern continuous and modular manufacturing approaches, modernisation of key advanced manufacturing technologies, and the innovative manufacturing and supply needed to deliver both existing and new therapeutic modalities.

Digital technologies including Artificial Intelligence, Machine Learning, Robotics will help to streamline manufacturing and supply processes and increase processes management along the supply chain to mitigate shortages, and enhance quality decision making. Measures for sustainable manufacturing & supply in response to climate change, and innovation in energy efficiency contributing to a circular economy should be in the forefront. However, they should be managed in such a way that they support a competitive and efficient European life sciences and biotechnology industry. EuropaBio recommends that priority areas in advanced manufacturing be identified for investment to enable a competitive and continuous transformation of the sector.

1 https://www.ema.europa.eu/en/documents/report/annual-report-use-special-contribution-orphan-medicinal-products-2020_en.pdf

EPSCO Council conclusions: EuropaBio calls for more pragmatic approach addressing access, availability and affordability of medicines


Download
EuropaBio on EPSCO conclusionsDownload

Share
Alexandra Simionca
Alexandra Simionca

Related posts

22/05/2025

Adisseo joins EuropaBio: Feeding Animals Sustainably Around the World


Read more
21/05/2025

Ensuring Biotech Integration in the Single Market


Read more
10/04/2025

EU biotechnology competitiveness for the future; high level dialogue with EVP Séjourné


Read more

Important links

  • Adisseo joins EuropaBio: Feeding Animals Sustainably Around the World
  • Ensuring Biotech Integration in the Single Market

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.